Apyx Medical (APYX) Q3 2026 Earnings Call Transcript

DATE

Nov. 5, 2026

CALL PARTICIPANTS

• President and Chief Executive Officer - Charlie Goodwin
• Chief Financial Officer - Matthew Hill

TAKEAWAYS

• Total Revenue -- $14.0 million, representing a 9% increase primarily driven by the Surgical Aesthetics segment.
• Surgical Aesthetics Revenue -- $13.0 million, growing 17.2% due to domestic AYON sales and international Renuvion generator demand.
• OEM Revenue -- $1.1 million, a 41.5% decrease resulting from lower sales volumes to existing customers.
• Domestic Revenue -- $9.7 million, an increase of 4% year over year.
• International Revenue -- $4.3 million, rising 22.1% driven by Renuvion adoption in markets such as South Korea.
• Gross Margin -- 64.2%, a slight decrease from 64.4% in the prior year period due to geographic and product mix.
• Operating Expenses -- $9.6 million, up from $9.1 million primarily due to higher salaries and related costs.
• Net Loss Attributable to Stockholders -- $1.8 million, or $0.04 per share, compared to $2.0 million, or $0.05 per share, in the third quarter of 2025.
• Adjusted EBITDA -- $0.4 million, improving from a loss of $0.1 million in the prior year period.
• Cash and Cash Equivalents -- $25.8 million as of Sept. 30, 2026, providing operational flexibility.
• Net Cash Used in Operating Activities -- $1.6 million, a reduction from $3.5 million used in the third quarter of 2025.
• Average Quarterly Cash Burn -- approximately $2 million, reflecting management's discipline in managing operations.
• Full-Year Revenue Guidance -- $59 million to $60 million, reaffirmed for the fiscal year ending Dec. 31, 2026.
• Full-Year Surgical Aesthetics Guidance -- $54 million to $55 million, assuming continued growth in body contouring technologies.
• Full-Year Operating Expense Guidance -- $41.0 million to $42.5 million, lowered from the previous target of less than $45 million.
• Gross Margin Guidance -- 63% to 65% for the full fiscal year.
• AYON Customer Mix -- 75% of sales were to existing Renuvion users and 25% were to new customers, reflecting cross-selling success.
• Tissue Quality Metrics -- 30% increase in elastin fiber density and 34% reduction in inflammation following Renuvion treatment, according to clinical data.
• Power Liposuction Surgeon Adoption -- approximately 70% of plastic surgeons, representing the target market for the new AYON handpiece.
• Operating EBITDA Milestone -- positive on a cumulative trailing 12-month basis, as reported by management.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

• Hill warned that domestic sales of standalone generators and global sales of single-use handpieces decreased during the period, offsetting growth in other areas.

SUMMARY

Apyx Medical Corporation (NASDAQ:APYX) reported growth across its Surgical Aesthetics segment as the company expanded the commercial rollout of its AYON Body Contouring System. Management stated that the integration of power liposuction capabilities serves as a pivotal catalyst for adoption, targeting a significant majority of practicing plastic surgeons. The company reaffirmed its full-year revenue expectations while tightening operating expense guidance, reflecting a focus on reaching sustained profitability. Management reported that the business has achieved positive EBITDA on a cumulative trailing 12-month basis. Future growth strategies include pursuing regulatory registrations in key international markets and capitalizing on the emerging patient pipeline generated by weight-loss medications.

• Goodwin noted the company is pursuing registration for AYON in Europe, the Middle East, and Latin American markets such as Brazil, Colombia, and Mexico.
• Management expects long-term demand for Renuvion and AYON as patients using GLP-1 weight-loss drugs seek to address skin laxity following significant weight reduction.
• Goodwin indicated that the reconstructive market represents a growth opportunity globally as it is a segment the company has not previously addressed.
• CEO Goodwin stated, "The AYON system was designed by surgeons to specifically close these clinical gaps," referring to workflow optimization and safety features.
• Pretreatment with Renuvion before fat transfer has demonstrated up to 40% higher fat graft retention in clinical papers.
• Management confirmed that all initial orders for the power liposuction handpiece were filled by the end of the third quarter.

INDUSTRY GLOSSARY

• AYON: An integrated body contouring platform combining fat removal, Renuvion technology, and electrosurgical capabilities.
• Renuvion: Proprietary helium plasma technology used for subdermal tissue contraction and skin tightening.
• GLP-1: Glucagon-like peptide-1 medications used for weight loss, which the company identifies as a long-term driver for skin-tightening procedures.
• OEM: Original Equipment Manufacturing segment where the company produces medical device components for other firms.
• Elastin: A protein in connective tissue that allows tissues in the body to resume their shape after stretching or contracting.
• Power Liposuction: A surgical technique using a reciprocating cannula to automate fat removal, reducing surgeon fatigue and improving efficiency.

Full Conference Call Transcript

Operator: Good morning, ladies and gentlemen, and welcome to the Apyx Medical Third Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jeremy Feffer from Lifesci Advisors. Please go ahead.

Jeremy Feffer: Thank you, and welcome, everyone, to our third quarter 2026 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer, and Matt Hill, Chief Financial Officer of Apyx. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including, without limitation, those identified in the Risk Factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing, and the company's other filings with the Securities and Exchange Commission.

Such factors May be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles, or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website. I would now like to turn the call over to Mr.

Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Please go ahead.

Charles Goodwin: Thank you, Jeremy, and thank you all for joining us today. Per our usual format on these quarterly calls, I will begin with a review of our performance over the past several months, and then turn the call over to Matt for a review of our third quarter 2026 financial results, along with our guidance for the full year 2026. We will then open the call for your questions. Let me begin with a review of a few key highlights from our third quarter 2026 performance. We delivered another quarter of strong year-over-year growth with total revenue of $14 million, an increase of 9% compared with the third quarter of 2025.

Growth was driven primarily by sales of AYON in the United States and Renuvion outside the United States, reflecting continued demand for our body contouring technologies. For the 3 and 9 months ended September 30, 2026, our Surgical Aesthetics segment grew over 17% and 26%, respectively, as compared to the same periods last year. We are pleased by the progress we have made with AYON in the 1 year since its full commercial launch. During this time, we have continued to build awareness of the platform and demonstrate the value of bringing fat removal, closed-loop contouring, Renuvion tissue contraction, and electrosurgical capabilities together in 1 integrated system.

We are building on a foundation with the broader commercial rollout of AYON's power liposuction capability consistent with the plans we outlined last quarter. Power liposuction uses a reciprocating cannula to support more efficient fat removal while reducing the physical effort required of the surgeon. We estimate approximately 70% of plastic surgeons use power liposuction, making this an important addition that broadens AYON's appeal. Therefore, the recent clearance and commercial launch of power liposuction was a pivotal catalyst in driving AYON's adoption. While the rollout remains in the early stages, feedback from surgeons has been very positive.

Power Lipo was designed directly into every AYON, and activation requires only a simple software update and the purchase of the handpiece and cannula. Clinicians can seamlessly deploy the full clinical AYON solution with no downtime. The legacy liposuction products on the market haven't moved the needle on safety and efficacy in 2 decades. The AYON system was designed by surgeons to specifically close these clinical gaps. By embedding next-generation safety and workflow optimization into a single, elegant system, we believe AYON establishes a new benchmark for surgical performance. It is uniquely positioned to be the global standard of care for plastic surgeons.

Renuvion remains central to our strategy, both as a standalone system and as an integrated part of AYON. Its tissue contraction capability complements fat removal, helping surgeons address skin laxity that remains after liposuction or significant weight loss. Continued demand for AYON and Renuvion reflects the value surgeons see in having these complementary technologies available for their patients. Our commercial strategy is supported by our continued commitment to building clinical evidence. Last quarter, we discussed studies reporting higher patient satisfaction and lower rates of abdominoplasty and surgical revision with Renuvion plus liposuction compared with liposuction alone, as well as improvements in cellulite appearance and skin laxity following combined Avéli and Renuvion treatment.

In September, we added to this evidence with a prospective study evaluating Renuvion's effect on biological markers associated with skin quality published in Plastic and Reconstructive Surgery – Global Open. The study enrolled 7 patients undergoing facelift surgery with 6 completing the 6-month follow-up. Tissue analysis at the visit showed 30% greater elastin fiber density and 34% less inflammation in treated tissue compared to untreated control areas. All 6 patients reported improvements in skin quality and satisfaction with their outcomes. These findings add direct human tissue evidence supporting the improvements surgeons and patients have observed with Renuvion and reinforce the value of evaluating tissue quality alongside tissue contraction.

We believe this is an important consideration in body contouring where achieving the desired results depends not only on removing the fat, but also addressing the quality and laxity of the skin that remains. Looking ahead, the continued adoption of GLP-1 medications is reshaping the body contouring patient population and creating what we believe is a meaningful long-term opportunity for our business. While these therapies are helping a growing number of patients achieve substantial weight loss, many are left with loose or lax skin and residual areas of fat that they want to address. As these patients reach or approach their target weight, we believe many will seek procedures that address these concerns more comprehensively.

By combining advanced fat removal with Renuvion's tissue contraction capabilities, Apyx positions us to help surgeons meet these needs. Our focus remains on transitioning this opportunity into broader adoption through continued commercial execution. Before I turn the call over to Matt, I want to recognize the Apyx team. We have successfully achieved our product development, regulatory, and sales goals, all while maintaining strict cost discipline. To that end, I am pleased to report that on a cumulative trailing 12-month basis, the company has achieved positive EBITDA. Now I will turn the call over to Matt for a review of our third quarter 2026 financial results in more detail along with our financial guidance for 2026.

Matthew Hill: Thanks, Charlie. Before I get started, please note that all references to our third quarter financial results will be on a GAAP and a year-over-year basis unless noted otherwise. As Charlie mentioned, total revenue for the third quarter of '26 increased 9% to $14 million compared to $12.9 million in the prior year period. Revenue for the Surgical Aesthetics segment increased 17%, or $1.9 million, to $13 million, compared to $11.1 million for the prior year period. This growth was driven by sales of AYON as we commenced our commercial launch in the third quarter of '25 and increased sales of generators internationally.

These increases were partially offset by decreases in domestic sales of standalone generators and sales of single-use handpieces globally. Turning to the OEM segment, sales decreased 41.5%, or approximately $0.7 million, to $1.1 million, for the third quarter of '26 compared to $1.8 million for the third quarter of '25. The decrease in OEM sales was due to a decrease in sales volume to existing customers. With the increased focus on Surgical Aesthetics, we expect OEM segment revenue will decrease for the year. Domestic revenue increased 4% year-over-year to $9.7 million, and international revenue increased 22% year-over-year to $4.3 million for the third quarter of 2026.

Gross profit for the third quarter of '26 increased 9% to $9 million, compared with $8.3 million in the prior year period. Gross profit margin for the third quarter of '26 decreased to 64.2% compared to 64.4% in the prior year period. The decrease is primarily attributable to geographic mix with international sales comprising a higher percentage of total sales and product mix within both the Surgical Aesthetics and OEM segments. These decreases were partially offset by an increase due to mix between our segments with Surgical Aesthetics comprising a higher percentage of total sales. Operating expenses increased to $9.6 million for the third quarter of '26 compared to $9.1 million for the prior year period.

The increase was mostly driven by a $0.4 million increase in salaries and related costs and a $0.2 million increase in selling, general, and administrative expenses, which was partially offset by a $0.2 million decrease in professional services. Loss from operations was $0.6 million, compared with a loss from operations of $0.8 million for the third quarter of 2025. Net loss attributable to shareholders was $1.8 million, or $0.04 per share, for the third quarter of '26, compared with $2 million or $0.05 per share in the prior year period. Adjusted EBITDA was $0.4 million for the third quarter of '26, compared to an adjusted EBITDA loss of $0.1 million for the third quarter of '25.

As a reminder, we provided detailed reconciliation from net loss attributable to stockholders to non-GAAP adjusted EBITDA in our earnings press release. For the 3 months ended September 30, 2026, net cash used in operating activities was $1.6 million compared to $3.5 million used in the prior year period. The decrease was primarily due to changes in working capital, combined with a reduction in net loss. As of September 30, 2026, the company had cash and cash equivalents of $25.8 million. We have maintained a solid cash position, managing to an average cash burn of approximately $2 million a quarter this year, providing substantial flexibility to support our ongoing operations and execute our strategic plan.

As you can see from our financial performance, we're very focused on growing the top line while prudently holding the line on operating expenses. Our continued focus on operating discipline, cash management, and financial performance positions us to navigate our upcoming obligations while maintaining our commitment to long-term value creation. Turning to our 2026 guidance, we're reaffirming our full-year revenue guidance in the range of $59 million to $60 million compared with $52.8 million reported for the year ended December 31, 2025.

Our guidance continues to assume Surgical Aesthetics segment revenue in the range of $54 million to $55 million, compared with approximately $45.3 million for 2025, and OEM revenue of approximately $5 million, compared with approximately $7.5 million for 2025. In addition, we now expect gross margins in the range of 63% to 64% and updated our total operating expense targets in the range of $41 million to $42.5 million for the full year. Previously, we stated operating expenses would be less than $45 million. This completes our prepared remarks. Charlie and I will now open the call for questions. Operator.

Operator: [Operator Instructions] Your first question comes from the line of Alex Fuhrman with Loop Capital Markets. Please go ahead.

Alex Fuhrman: Can you talk a little bit more about the lower operating expense target for the year and what's driving the improved profitability here? Obviously, it sounds like very strong demand here, especially with the addition of Power Lipo here, but would love to get a better understanding of the improved profitability here as well.

Charles Goodwin: Yes. No, I appreciate the question. Look, we've stated that we want to get this business to profitability as quickly as we can, and we're very proud of the effort that the team has put forward. For the last trailing 4 quarters, we're actually EBITDA positive. And so we've done a very good job of growing the top line, but also managing the bottom line. And you're seeing the growth go straight to the bottom line, and that's why you get the improvement. We had always stated at the beginning of the year that we weren't going to spend more than $45 million, and obviously through the first 3 quarters, we're way under that.

And so now we just tightened that range of what we will spend between now and the end of the year.

Alex Fuhrman: Okay, that's really helpful. And then, obviously, not trying to get you to give us formal guidance for next year or anything, but just can you give us a little bit of understanding of just how to frame up where you are in the rollout of the new all-in-one system? Is that expected to be a continued tailwind into the first half of next year?

Charles Goodwin: Well, I would say that the tailwind for all-in-one is for multiple years. Remember, we're just getting started in the United States. We actually just got PowerLipo out to everybody that had bought it. And so we think that AYON will have growth for a lot of years to come. And the other side of that is right now we are only selling it in the United States. And obviously we're working on registration in a lot of the key markets outside the United States and would expect to have those at some point to be able to start selling AYON on a worldwide basis. Doctors all over the world are seeing AYON at the show. They're talking about it.

They're hearing about it. And, you know, we're just excited to get it registered and to get it out there.

Alex Fuhrman: Yes, that will be really exciting to see that. Thank you, Charlie, and congratulations again on the strong results.

Charles Goodwin: Thanks, Alex.

Operator: Your next question comes from the line of Sam Eiber with BTIG. Please go ahead.

Sam Eiber: Maybe just following up on that last question, are there any key markets we should be looking out for in terms of timelines when AYON might get the necessary regulatory approvals? I know Renuvion has been doing well in certain markets, but curious if you're able to give us any timelines on AYON and some of the larger OUS markets you play in today.

Charles Goodwin: Yes, timelines. The answer to that is no. Obviously, when we get registration in some of these key areas, we'll obviously let the market know if it's important. But obviously the markets that we were really after and really want right away are obviously Europe, the Middle East, and then key countries in Latin America. And those key countries in Latin America are namely Brazil, Colombia, and Mexico.

Sam Eiber: Okay, very good. Fair enough. And then maybe I can just use 1 follow-up question here on what's resonating maybe more with some of the doctors that have adopted AYON at this point. Is it more so the clinical benefits that they're seeing? Is it the economics on the faster procedures and greater patient throughput? Or maybe it's a combination of the two, but curious what you're hearing from the field.

Charles Goodwin: Yes, it's all of the above. Doctors are really noticing the technological advances in the liposuction, and the doctors that see it and have it are talking a lot about it. They are seeing that their patients actually recover faster because they have less bruising and less downtime from traditional lipo that they were using before. And so there's definitely that clinical aspect of it, and having the integrated system for fat transfer and everything else is key to them.

And there are doctors that are using it to actually bring in new patients and talk to patients that they've got the latest and greatest technology and are able to either convert more patients into having procedures with them or even in some cases charging more for those procedures because they're using the latest and greatest technology. And then there's the whole efficiency piece for the doctors and their teams where they're able to save time and do that. And so Apyx has a lot of drivers for the doctors, their patients, and their practices. It's now our job on the commercial side to make sure that everybody understands that—the doctors themselves, their staff, and the patients also.

So we've still got work to do from a worldwide basis, but we are even more excited as we sit here today that we think that AYON will be the standard of care for body contouring all over the world. It really is being received that well in the field.

Sam Eiber: Okay, very good. Thanks for taking the questions, guys.

Operator: Your next question comes from the line of [ Tollef Kohrman ] with Craig-Hallum. Please go ahead.

Unknown Analyst: So for AYON growth, how much of that was competitive conversions? And then for my second question, could you speak to the pipeline of PowerLipo? Thank you very much.

Charles Goodwin: So Power Lipo, we were able to fill all the orders of Power Lipo just within the end of this last quarter. So everybody that had a Power Lipo system could actually get their handpiece, at least 1 of them. And I think now we've been able to get everybody all of theirs since then. And now is the first time that if you actually bought an AYON today, you could actually get Power Lipo with it. Okay. So that's the first one.

As far as new customers, if you look at where we've done so far, about 75% of our AYON sales have been to existing Renuvion customers and about 25% to brand-new customers that have never been part of Apyx.

Unknown Analyst: Great. Thank you.

Operator: Your next question comes from the line of Danny Stauder with Citizens JMP. Please go ahead.

Daniel Stauder: I wanted to ask on fourth quarter, how should we be thinking about capital versus handpiece mix in terms of what's implied for fourth quarter sales? And as we think out to 2027, what's a good way to frame that, just considering some of the puts and takes we saw in 2026? Thank you.

Charles Goodwin: Yes, so if you look at handpieces in particular, it's always tough to look at it on a quarter-by-quarter basis. We obviously look at it on a year-by-year basis because it depends on whether some large customers when they place their order to where it is. And so for the first 3 quarters from a handpiece perspective, we're right where we thought we were going to be, and we would expect Q4 obviously to be a very good handpiece quarter because that's where the greatest number of procedures are done in Q4 as opposed to Q3. So we think that Q4 will be a good handpiece quarter as well as a good capital quarter. It's always our best capital quarter.

And so we're looking for both of those things to happen. As far as the comparison in Q4, remember that last year we started pre-selling AYON in May when we got approval. And so we were selling AYONs basically for over half of a year, and we didn't actually ship those AYONs until Q3 and Q4. So from a comparison basis, there were 6 months of sales that were put into the last quarter, basically. So from a comparison, it's not an apple-to-an-apple comparison on a regular quarter, but that's the last quarter of this. And then as we move into '27, obviously the comparisons will be a lot easier to go after.

Daniel Stauder: That's really helpful. Thank you. And then just 1 follow-up on some of the terms of the international opportunity. Just in terms of AYON, could you talk about those markets? I mean, is that 70% of plastic surgeons using Power Lipo, is that consistent abroad? And is there any reason that AYON might be more or less attractive in some of these international markets, just depending on the different trends and idiosyncratic characteristics there? Thank you.

Charles Goodwin: Yes, no, it's a good question because there are some differences there. Power Lipo is about the same. That is not different. But what is different in Europe especially and in various other countries is a lot of the liposuctions are done in the hospital setting and done by teams of doctors. And that makes Apyx even that much more of a value to the doctors and their teams because of the simultaneous activation. Remember, you can do up to 4 things at the same time with AYON. So that simultaneous activation is a huge benefit in places like Europe where doctors and their teams do that.

The other side of it, too, is because they're done in the hospital, a lot of the reconstructive doctors can be using AYON also. And that is an area that, quite honestly, they weren't really using Renuvion before. Now they're going to get exposure to Renuvion, too, on the reconstructive market. And so the reconstructive market is obviously an upside for us all over the world because it's really not a market that we have called on before. So there are some differences outside the United States because of where the body contouring procedures are done.

Daniel Stauder: Great. Thanks so much for the question. Thank you.

Operator: Your next question comes from the line of Yi Chen with H.C. Wainwright. Please go ahead.

Unknown Analyst: Good morning, this is Katie on for Yi. Thinking about AYON, for the systems that were installed earlier in the launch, do you find that customers are adopting the full workflow or selectively using different pieces of it, using Renuvion tissue contraction in a greater proportion of their cases? And what kind of gives you a clue that one of these customers is going to be a broader utilizer versus more selective?

Charles Goodwin: Yes, so the answer to that is yes, more doctors are using the full suite of AYON, where we're seeing that especially is on the 2 different liposuctions. There's a lot of doctors that only used power liposuction and didn't have ultrasonic liposuction, and now we're seeing them use the ultrasonic liposuction also because it is a great tool for them to use in these procedures. So we are seeing that. As far as the Renuvion usage, as I stated earlier, about 75% of the AYONs that we've sold have been to Renuvion customers, and obviously they were using Renuvion before, and so that utilization is basically the same that it was.

But where we are obviously seeing an uptick in Renuvion and them using the whole system is into the 25% of those that are new customers, new to Apyx. And we know that they're using Renuvion obviously because they're buying handpieces.

Unknown Analyst: Quick follow-up, you had at 1 point mentioned a mechanism paper that will be published for Renuvion. Do you guys have any update on that?

Charles Goodwin: Yes, that paper was—I don't think it was a mechanism paper. I think it was the paper that we highlighted in the prepared remarks. It was for skin quality. And if you look at Renuvion, we have done a very good job of publishing and talking about Renuvion for skin retraction, okay, and that is obviously very important, skin tightening. It's used after liposuction, it's used in body contouring, and that will remain obviously important. But we've done 2 other studies that show versatility of Renuvion itself, and 1 is the pretreatment of areas before fat transfer.

And if you pre-treat the area with Renuvion before fat transfer, we have papers that show up to 40% higher retention of the fat graft. And so that is incredibly important when you're doing fat transfer. And then the last part of that was the study that just came out in September that talked about skin quality. And that skin quality is incredibly important and we think is going to be a driver for Renuvion and new users for Renuvion because the skin is your largest organ. And as you're doing the skin tightening, what actually helps is if the quality of your skin can get better.

And in this study, we had over a 30% improvement of elastin and about the same improvement in inflammation, and that improves the quality of the skin. And there hasn't been anything that has shown an improvement in elastin out there. So we think that is going to be a very important paper for us and to keep talking about how Renuvion will keep being a driver of this business for many years to come also.

Unknown Analyst: Thank you very much.

Operator: Your next question comes from the line of Jeremy Pearlman with Maxim Group. Please go ahead.

Jeremy Pearlman: Just firstly, are there any remaining investments that are either planned or required to support AYON now that you've moved into the full commercial launch?

Charles Goodwin: Yes. Now that we've made full commercial launch, now we've made all the investments that we're going to make for that. The only thing that we have ever mentioned before is, as I alluded to on 1 of the other questions, there is an opportunity in the reconstructive space, in the hospitals, in the United States, and we need to figure out how we're going to actually do that—more on that when it comes. But as far as investments come for this year, that is all baked into what we're doing. And then we've stated that getting to profitability for this company is incredibly important for us, and we're going to do it as fast as we can.

Jeremy Pearlman: Okay, understood. And then just another question relating, maybe you can help us understand some of the divergence between domestic revenue grew this year only 4% and then international was 22% this quarter. So is that just because of the way that, you know, the winding down of the OEM business and then the transition from the limited to the full commercial launch, which is a timing issue and due? Should we expect that gap to be covered up by the domestic revenue going forward? Thanks.

Charles Goodwin: Yes. So if you remember from our guidance, we've given guidance for the year that we will grow the Surgical Aesthetics business 20%, and we're at 26%, I think, after 3 quarters. And so what you're seeing in the U.S. business is, as I stated last year when we launched AYON, we got approval in May, And we started to sell AYON units that we could not ship until September, October, November, and December. So when you're looking at a comparison, all of the months that we've had before September, there was no AYON in that number. And now you're getting AYON in that number for September, October, November, and December.

And that's why the growth rate appears to be going down. It is from a mathematical point of view, but we were selling AYONs all last year and shipped them all just in 4 months. So that's really the difference and why you're seeing that now in the third quarter. And then obviously in the fourth quarter, you'll see that the growth rate in the United States won't be as high either because of those comparisons of AYON that were shipped in October, November, and December. As far as outside the United States, that still remains to—especially Korea has been having a very good year, their first year, obviously, launching Renuvion.

And that's where a lot of the growth is from outside the United States.

Jeremy Pearlman: Okay. Thank you for answering my question. I'll hop back in the queue.

Operator: I am showing no further questions at this time. This concludes our question-and-answer session. I will now hand the conference back to Charlie Goodwin for his closing comments.

Charles Goodwin: Thank you, everybody, for joining us today. We are pleased with the momentum in the business this quarter and look forward to executing on the expanded commercial strategy we discussed as we continue to build market share for the AYON platform. I appreciate the continued support of our shareholders, our staff, and thank you all for joining the call today. Thank you.

Operator: Today's conference call for Apyx Medical has now concluded. Thank you for your participation. You may now disconnect.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.